NICE recommends Mavanclad as a treatment for multiple sclerosis.-Merck KGaA.

Merck KGaA, announced that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (UK) has issued a final appraisal determination (FAD) recommending Cladribine Tablets (Mavanclad) as an option for treating highly active multiple sclerosis in adults.

Use of Cladribine Tablets is recommended only if the person has: rapidly evolving severe relapsing–remitting multiple sclerosis, that is, at least two relapses in the previous year and at least one T1 gadolinium-enhancing lesion at baseline MRI or relapsing–remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as one relapse in the previous year and MRI evidence of disease activity. This decision comes only two months after the European Commission granted marketing authorization for Mavanclad in August 2017.